Effect of habb waja ul mafasil in management of Cervical Spondylosis

Clinical study of Cervical Spondylosis (waja al-Unuq) with therapeutic evaluation and safety of Habb Waja al Mafasil in its management

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/032263

Enrollment

Registered

2021-03-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M478- Other spondylosis

Interventions

Intervention1: Habb Waja ul mafasil: ingredients: Sibr(140gms), halela zard(35gms), suranjan(35gms), saqmooniya(17.5gms) method of prepration: all the above ingredients will be grounded to fine powder

Eligibility

Inclusion criteria

Inclusion criteria: -Patients between 20 and 70 years of age. -Male, Female and transgender -Clinically diagnosed patients of cervical spondylosis -Patients who have agreed to sign the informed consent form and follow up the protocol

Exclusion criteria

Exclusion criteria: Patients below 20 and above 70 years. Trauma Local wound and infection over neck. Psychomotor syndrome Patients with history of systemic diseases like, diabetes, cardiovascular diseases, impaired renal and hepatic functions, HIV, T.B and COPD. Patients who refuse to give the written consent for the study. Pregnancy and lactating women. Any of them not covered under inclusive criteria.

Design outcomes

Primary

Measure	Time frame
relief in signs and symptoms of cervical spondylosisTimepoint: 30 days	—

Secondary

Measure	Time frame
Haematological,biochemical and radiological assessmentTimepoint: 30 days	—

Countries

India

Contacts

Public ContactDr Shameem Ahmad Rather

Regional Research Institute of Unani Medicine

shameem.rather.sr@gmail.com7889584083

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026